Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;11(5):e333-e340.
doi: 10.1016/S2352-3018(24)00063-8. Epub 2024 Apr 8.

Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians

Affiliations
Review

Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians

Andrés Esteban-Cantos et al. Lancet HIV. 2024 May.

Abstract

In individuals receiving antiretroviral therapy (ART), persistent low-level viraemia not attributed to suboptimal ART adherence, detrimental pharmacological interactions, or drug resistance is referred to as non-suppressible viraemia (NSV). This Review presents recent findings in the virological characterisation of NSV, revealing that it consists of one or a few identical populations of plasma viruses without signs of evolution. This finding suggests that NSV originates from virus production by expanded HIV-infected cell clones, reflecting the persistence of the HIV reservoir despite ART. We discuss knowledge gaps regarding the management and the clinical consequences of NSV. The prevalence of NSV remains to be precisely determined and there is very little understanding of its effects on virological failure, HIV transmission, secondary inflammation, morbidity, and mortality. This issue, along with the absence of specific recommendations for the management of NSV in HIV clinical guidelines, underscores the complexities involved in treating individuals with NSV.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests AE-C has received payment or honoraria for presentations from Gilead Sciences. RM has received payment or honoraria for presentations, and advisory fees; has participated on advisory boards; and has received support for attending meetings from Gilead Sciences, ViiV Healthcare, Janssen, Thera Technologies, GlaxoSmithKline, and Merk Sharp & Dohme. AP-M has received payment or honoraria for presentations and support for attending meetings from ViiV Healthcare, Gilead Sciences, and Merk Sharp & Dohme. FP has received consulting and speaker fees and support for attending meetings from Gilead Sciences, Janssen, Merk Sharp & Dohme, and ViiV Healthcare. JRA has received consulting fees and support for attending meetings from Gilead Sciences, ViiV Healthcare, Aelix, Janssen, and Merk Sharp & Dohme. All other authors declare no competing interests.

Similar articles

Cited by

Publication types

Substances

LinkOut - more resources